Contrafect to test S. aureus therapy in Phase III despite Phase II miss

Exebacase (CF-301) from ContraFect Corp. (NASDAQ:CFRX) plus standard of care (SOC) antibiotics missed the primary endpoint of improving clinical

Read the full 199 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE